Business
Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights
Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinop
About this update from Geron Corporation
[{"type":"image","alt":"Geron Corporation","displaySize":"","headline":null,"caption":"Geron Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/3941ce2a92d29d3b5d821029ba123e55"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/u55p6QCS0HHXxDfBfZZ2lw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNg--/https://media.zenfs.com/en/globenewswire.com/3941ce2a92d29d3b5d821029ba123e55","width":290,"height":94}},"lazy":false},{"type":"text","content":"Achieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025","length":132,"tagName":"p"},{"type":"text","content":"Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively","length":180,"tagName":"p"},{"type":"text","content":"Strengthened leadership team with appointments of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate Secretary and Patricia S. Andrews and Constantine Chinoporos to Board of Directors ","length":212,"tagName":"p"},{"type":"text","content":"Ended Q1 2026 with cash, cash equivalents, restricted cash and marketable securities of $341 million","length":120,"tagName":"p"},{"type":"text","content":"Company to host conference call and webcast today, May 6, 2026, at 8:00 a.m. ET","length":79,"tagName":"p"},{"type":"text","content":"FOSTER CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the first quarter of 2026 and recent business highlights.","length":290,"tagName":"p"},{"type":"text","content":"“We are encouraged by RYTELO demand and net revenue growth in the first quarter. Our refocused commercial strategy, energized team, and commitment to execute with excellence position us well to continue building on these results,” said Harout Semerjian, President and Chief Executive Officer of Geron. “We also made progress on our potential European lower-risk MDS commercial strategy for RYTELO, with the goal of maximizing its value while preserving pricing integrity in the U.S. We plan to provide an ...